NEW DELHI: A consortium of experts for anti-COVID is working towards developing therapeutic antibodies to fight against COVID-19. They are also being assisted by the Department of Biotechnology for this discovery.
Vijay Chaudhary from the University of South Delhi Campus-Centre for Innovation in Infectious Disease Research Education and Training (UDSC-CIIDRET) is leading one such research with the aid of Department of Biotechnology in the Ministry of Science and Technology.
Chaudhary's team is working towards isolating genes encoded with antibodies, which are capable of neutralising SARS-CoV02 (Coronavirus) by using a large antibody library. The library is already available in-house and there is a library made from the cells of the patients who have recovered from the COVID-19 infection.
The genes of these antibodies will be used to produce recombinant antibodies in the labs. If they are successful in stabilising the virus, will become the permanent source od antibodies against the virus. It will be used for therapeutic and prophylactic purposes, both.
This project is being led by Chaudhary as a part of an anti-COVID consortium. Amulya Panda at National Institute of Immunology and Sanjay Singh at Gennova Biopharmaceutical Limited, Pune (GBL) are also a part of this project.
A statement was also given by the Department of Biotechnology, which said, "Today such therapeutic antibodies can be produced in the laboratory by DNA-based recombinant technologies. Efforts are in full swing globally to produce therapeutic antibodies against SARS-CoV-2."